Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian …

MK Lo, JR Spengler, SR Welch… - The Journal of …, 2020 - academic.oup.com
MK Lo, JR Spengler, SR Welch, JR Harmon, JAD Coleman-McCray, FEM Scholte
The Journal of infectious diseases, 2020academic.oup.com
In the absence of approved vaccines and therapeutics for use in humans, Nipah virus (NiV)
continues to cause fatal outbreaks of encephalitis and respiratory disease in Bangladesh
and India on a near-annual basis. We determined that a single dose of a lipid nanoparticle
nucleoside-modified messenger RNA vaccine encoding the soluble Hendra virus
glycoprotein protected up to 70% of Syrian hamsters from lethal NiV challenge, despite
animals having suboptimally primed immune responses before challenge. These data …
Abstract
In the absence of approved vaccines and therapeutics for use in humans, Nipah virus (NiV) continues to cause fatal outbreaks of encephalitis and respiratory disease in Bangladesh and India on a near-annual basis. We determined that a single dose of a lipid nanoparticle nucleoside-modified messenger RNA vaccine encoding the soluble Hendra virus glycoprotein protected up to 70% of Syrian hamsters from lethal NiV challenge, despite animals having suboptimally primed immune responses before challenge. These data provide a foundation from which to optimize future messenger RNA vaccination studies against NiV and other highly pathogenic viruses.
Oxford University Press